The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, was held as scheduled on Friday. As previously announced, it was a formal meeting for the start-up and review of routines and equipment.
– I am very excited about the study and look forward to start patient recruitment, says James A. Eastham, Chief of the Urology Service at Memorial Sloan Kettering Cancer Center.
FDA has approved SpectraCure's new protocol for clinical trials, enabling more patients to be treated at a faster rate, which increases the basis of analysis for further clinical trials. As previously announced, the updated software, the new, more user-friendly interface, which communicates with the dose planning platform IDOSE and controls the hardware has also been approved. The enhanced graphics mean higher resolution images and a more natural workflow for the doctors in the study. It becomes easier and faster to create a treatment plan in the system and the doctors also get better reconnection during the treatment itself.
For further information contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90.
Certified Adviser is G&W Fondkommission, e-mail: email@example.com, phone: +46(0) 8 503 000 50.
This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on March 16th, 2020 13:15.
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as “Interstitial Photodynamic Therapy”, PDT, a treatment methodology suitable for internal solid tumors of various kind e.g. prostate and abdominal glands, but also other indications such as cancer tumors in the head and neck region. www.spectracure.se